OVITRELLE 250MCG/0.5ML INJECTION

Dosage

Children: Refer to specific drug information for paediatric dosing guidelines, as this will also vary.

Adults: Refer to specific drug information for dosing guidelines, as this will vary widely.

Mechanism of action

The mechanism of action for 'alfa' cannot be defined without specific identification of the drug. Each compound named 'alfa' will have distinct mechanisms, typically involving receptor interaction, enzyme inhibition, or modulation of physiological pathways.

Pharmacodynamics

Pharmacodynamics will vary widely depending on the specific agent referred to as 'alfa'. Generally, pharmacodynamics describes how a drug affects the body, including its therapeutic effects, side effects, and the relationship between drug concentration and effect.

Pharmacokinetics

The pharmacokinetics of 'alfa' would also depend on the particular drug profile, including absorption, distribution, metabolism, and excretion (ADME). Parameters such as bioavailability, half-life, and clearance rates would need to be defined based on the specific agent.

Pregnancy

Consult healthcare provider for risk assessment.

Breast-feeding

Consult healthcare provider for risk assessment.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Infertility in women
• Anovulation
• Ovulation induction
• Hypogonadism in men
• Testicular descent in cryptorchidism

Dosage

Children: Refer to specific product labeling or clinical guidelines for appropriate dosing based on indication and patient factors.

Adults: Refer to specific product labeling or clinical guidelines for appropriate dosing based on indication and patient factors.

Mechanism of action

Choriogonadotropin binds to the luteinizing hormone (LH) receptor, stimulating the production of sex hormones such as testosterone and progesterone. This mimicry of LH action promotes ovarian follicle maturation and ovulation in women, and stimulates Leydig cells in the testes to produce testosterone in men. This hormone also plays a vital role in the maintenance of the corpus luteum during the early stages of pregnancy.

Pharmacodynamics

Choriogonadotropin has a half-life ranging from 24 to 36 hours, and its pharmacodynamic effects are primarily mediated through the stimulation of LH receptors. It enhances the secretion of gonadal steroids, which are essential for reproductive function. The pharmacodynamic response can vary based on the patient's hormonal milieu and the dosing regimen employed.

Pharmacokinetics

Choriogonadotropin is administered via subcutaneous or intramuscular injection, leading to systemic circulation. The absorption is relatively rapid, with peak serum concentrations occurring within 24 to 48 hours post-injection. The elimination of hCG is primarily through the kidneys, with a small fraction metabolized in the liver. Its effects can last several days, particularly in the context of reproductive therapies.

Contra-indications

• Hypersensitivity to choriogonadotropin or any of its excipients
• Pregnancy
• Ovarian cysts or enlargement not due to polycystic ovary syndrome
• Precocious puberty
• Androgen-dependent tumors

Adverse effects

• Headache
• Fatigue
• Injection site reactions
• Nausea
• Vomiting
• Ovarian hyperstimulation syndrome (OHSS)
• Multiple pregnancies
• Abdominal pain

Interactions

• Corticosteroids may enhance the risk of OHSS
• Other gonadotropin treatments may have additive effects

Precautions

• Use with caution in patients with a history of thromboembolic disorders
• Monitor for OHSS in women undergoing assisted reproductive technology
• Assess ovarian reserve before treatment

Pregnancy

Choriogonadotropin is contraindicated in pregnancy.

Breast-feeding

There are no adequate and well-controlled studies in breastfeeding mothers, caution is advised.

Storage

Store at 2°C to 8°C. Do not freeze. Protect from light.

Formulations

• Injection solution